Literature DB >> 3631942

Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.

H C Standiford, G L Drusano, A Forrest, B Tatem, K Plaisance.   

Abstract

We compared ciprofloxacin (200 mg) with cefotaxime (2 g) when each was administered intravenously over a 30-min period to six volunteers in a crossover manner 1 week apart. To integrate the pharmacologic and microbiologic activity, inhibitory and bactericidal activities in serum were obtained for both antibiotics 1 and 6 h after administration against 10 strains of Escherichia coli, 10 strains of Klebsiella pneumoniae, 15 strains of Pseudomonas aeruginosa, and 10 strains each of methicillin-susceptible and -resistant Staphylococcus aureus. Geometric mean bactericidal titers for E. coli 1 h after the infusion were 1:60 for ciprofloxacin and 1:252 for cefotaxime, and for K. pneumoniae they were 1:20 and 1:256, respectively. However, geometric mean titers were poor for both antibiotics against methicillin-susceptible S. aureus (less than 1:2 for ciprofloxacin versus 1:5 for cefotaxime) and methicillin-resistant S. aureus (less than 1:2 for both antibiotics), as well as against P. aeruginosa (1:3 for ciprofloxacin versus 1:2 for cefotaxime). These data suggest that ciprofloxacin may be useful for the treatment of serious infections caused by E. coli and K. pneumoniae. However, caution is suggested when this dose of ciprofloxacin is used in situations in which septicemia is caused by P. aeruginosa or S. aureus and originates outside the urinary tract.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3631942      PMCID: PMC174899          DOI: 10.1128/AAC.31.8.1177

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

Review 2.  Increasing occurrence of methicillin-resistant Staphylococcus aureus in the United States.

Authors:  J M Boyce; W A Causey
Journal:  Infect Control       Date:  1982 Sep-Oct

3.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.

Authors:  M Johnson; P Miniter; V T Andriole
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; I Cabezudo; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  A randomized, controlled trial of cefoperazone vs. cefamandole-tobramycin in the treatment of putative, severe infections with gram-negative bacilli.

Authors:  J W Warren; E H Miller; B Fitzpatrick; D E DiFranco; E S Caplan; J H Tenney; W C Anthony
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

10.  Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections.

Authors:  M J Oblinger; J T Bowers; M A Sande; G L Mandell
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec
View more
  4 in total

1.  Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

Authors:  M Dan; F Poch; C Quassem; R Kitzes
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

2.  Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers.

Authors:  M P Weinstein; R G Deeter; K A Swanson; J S Gross
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers.

Authors:  D Israel; J G Gillum; M Turik; K Harvey; J Ford; H Dalton; M Towle; R Echols; A H Heller; R Polk
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 4.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.